clinical trial · NCT06607185
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company·phase1·active not recruiting·n = 750
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal CancerAdvanced Solid TumorMetastatic Solid TumorLY4066434.CetuximabNab paclitaxelGemcitabineOxaliplatinLeucovorinIrinotecan5Fluorouracil
brief summary
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.
started
Oct 21, 2024
primary completion
Jan 1, 2030
completion
Jan 1, 2030
last updated
Apr 22, 2026
official title
A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol